Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-05T02:53:54.861Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapina al descubierto en trastorno obsesivocompulsivo resistente al tratamiento antidepresivo

Published online by Cambridge University Press:  12 May 2020

M. A. Crocq ,
Ph. Leclercq ,
M. S. Guillon  and
P. E. Bailey
M. A. Crocq
Affiliation:
Centro hospitalario, BP 29,68250Rouffach, Francia
Ph. Leclercq
Affiliation:
68100Mulhouse, Francia
M. S. Guillon
Affiliation:
Centro hospitalario, BP 29,68250Rouffach, Francia
P. E. Bailey
Affiliation:
Centro hospitalario, BP 29,68250Rouffach, Francia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

olanzapinatrastorno obsesivo-compulsivoterapia de aumentoTOC no sensible al tratamiento
Type
Carta al Director
Information
European Psychiatry (Ed. Española) , Volume 10 , Issue 2 , March 2003 , pp. 130 - 131
Copyright
Copyright © European Psychiatric Association 2003

References

Bibliografía

Marazziti, D.Pallanti, S.Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiaty 1999;156:1834-5.Google ScholarPubMed
Marusic, A.Farmer, A.Antidepressant augmentation with lowdose olanzapine in obsessive-compulsive disorder. Br J Psychiatry 2000;177:567.CrossRefGoogle Scholar
Weiss, E. L.Potenza, M. N.McDougle, C. J.Epperson, C. N.Olanzapine addition in obsessive compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-7.CrossRefGoogle Scholar
Koran, L. M.Ringold, M. D.Elliott, M. A.Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000;61:5l4.CrossRefGoogle ScholarPubMed
Bogetto, F.Bellino, S.Vaschetto, P.Ziero, S.Olanzapine augmentation of obsessive-compulsive disorder: a 12-week open trial. Psychiatry Res 2000;96:91-8.CrossRefGoogle ScholarPubMed
McDougle, C. J.Epperson, C. N.Pelton, G. H.Wasylink, S.Price, L. H.A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794–801.CrossRefGoogle ScholarPubMed
McDougle, C. J.Goodman, W. K.Leckman, J. F.Lee, N. C.Heninger, G. R.Price, L. H.Haloperidol addition in fluvoxaminerefractory obsessive-compulsive disorder. A doubleblind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-8.CrossRefGoogle Scholar
Bymaster, F. P.Calligaro, D. O.Falcone, J. F.Marsh, R. D.Moore, N. A.Tye, N. C., et al.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87–9G.CrossRefGoogle ScholarPubMed
Pauwels, P. J.5-HT 1B/D receptor antagonists. Gen Pharmacol 1997;29:293–303.CrossRefGoogle ScholarPubMed